Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.

Eli Lilly shares climbed 32% last year but have slumped more than 16% since October after the company reported third quarter sales of the two drugs below Wall Street’s expectations, prompting ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.

Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year. The maker of weight-loss drugs Mounjaro and Zepbound said sales of the drugs grew ...

(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...

Eli Lilly’s (LLY) shares slumped over 8% on Tuesday after the company projected fourth-quarter sales of its weight-loss drug Zepbound and diabetes treatment Mounjaro to fall short of Wall Street ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...

Eli Lilly LLY2.29%increase; green up pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...

Eli Lilly expects 2025 revenue between $58 billion and $61 billion. The company sees 2024 revenue around $45 billion, 32% above sales from the previous year. The company noted strong sales from ...